Dermatology | Page 3 of 16 | Links Medicus Content Curation & Alerts in Medicine

Systematic Review: Strategies for using topical corticosteroids in children and adults with eczema.

21 Mar, 2022 | 08:33h | UTC

Strategies for using topical corticosteroids in children and adults with eczema – Cochrane Library

Summary: What is the best way to use topical corticosteroids to treat people with eczema? – Cochrane Library

Commentary on Twitter

What is the best way to use topical #corticosteroids to treat people with #eczema?
"Generally, stronger topical corticosteroids are probably more effective than weaker preparations". https://t.co/iaH6fzyXL4

Read the latest evidence from @CochraneSkin @CebdNottm pic.twitter.com/f01BO2FyDs

— Cochrane UK (@CochraneUK) March 17, 2022

Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.

18 Mar, 2022 | 08:09h | UTC

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly

RCT: Oral contezolid vs. linezolid in adults with complicated skin and soft tissue infections.

18 Mar, 2022 | 07:54h | UTC

A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections – Journal of Antimicrobial Therapy (link to abstract – $ for full-text)

Commentary on Twitter

Phase III efficacy & safety of oral contezolid Vs linezolid in adults with c.SSTIs
📌Non inferior
📌Interestingly:Contezolid demonstrated significant lower incidence thrombocytopenia (0% Wow vs 2.3%) & leucopenia (0.3% vs 3.4%) than linezolid
📌QIDP https://t.co/wSvxUInnkZ

— Antibiotic Steward Bassam Ghanem (@ABsteward) March 11, 2022

Follow-up data from 2 randomized trials: efficacy and safety of Upadacitinib in patients with moderate to severe atopic dermatitis.

18 Mar, 2022 | 07:48h | UTC

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology

Systematic Review: Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.

14 Mar, 2022 | 01:20h | UTC

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome – Cochrane Library

Summary: Which treatments that affect the whole body work best to treat severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis)? – Cochrane Library

Review: Mycobacterial skin infection.

14 Mar, 2022 | 00:59h | UTC

Mycobacterial skin infection – Current Opinion in Infectious Diseases

RCT: Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis.

10 Mar, 2022 | 10:27h | UTC

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial – The Lancet Rheumatology (link to abstract – $ for full-text)

Commentary: COMPLETE-PsA: Adding leflunomide to methotrexate may improve outcomes – medwireNews

Commentary on Twitter

NEW RESEARCH—A double-blind, placebo-controlled, randomised, trial comparing #methotrexate monotherapy with methotrexate plus #leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA) https://t.co/Fln7RlNl36 #LancetRheumatology pic.twitter.com/EqWSeHZQA2

— The Lancet Rheumatology (@TheLancetRheum) March 3, 2022